Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821219 | 0.93 | PPARG (0.60) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1820687 | 0.90 | PPARG (0.57) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1822881 | 0.90 | PPARG (0.56) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1820662 | 0.89 | PPARG (0.55) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1820729 | 0.89 | PPARG (0.55) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1821913 | 0.88 | PPARG (0.54) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1820942 | 0.87 | PPARG (0.54) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1818386 | 0.87 | PPARG (0.54) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL19184630 | 0.86 | PPARG (0.41) | PPARGMLNRAKT1LMNARECQL | |
| SCHEMBL1818946 | 0.86 | PPARG (0.52) | PPARGMLNRAKT1LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | claimed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | claimed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9447058-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-9156775-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | PPARG 409/4885MLNR 3458/4885AKT1 641/4885 |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PPARG 686/4885MLNR 3929/4885AKT1 195/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PPARG 686/4885MLNR 3929/4885AKT1 195/4885 |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PPARG 686/4885MLNR 3929/4885AKT1 195/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PPARG 686/4885MLNR 3929/4885AKT1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.